APVO - Aptevo Therapeutics Inc.
6.4
-0.060 -0.937%
Share volume: 5,466
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.26%
PREVIOUS CLOSE
CHG
CHG%
$6.46
-0.06
-0.01%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-08-2024 | 08-08-2024 | 11-07-2024 | 02-14-2025 | 05-15-2025 | 08-11-2025 | 11-06-2025 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | ||||
| Operating expenses | 6.983 M | 6.024 M | 5.213 M | 6.382 M | 6.480 M | 6.226 M | 7.610 M | |
| Selling general and admin | 3.231 M | 2.381 M | 2.110 M | 2.502 M | 2.847 M | 2.898 M | 3.566 M | |
| Research and development | 3.752 M | 3.643 M | 3.103 M | 3.880 M | 3.633 M | 3.328 M | 4.044 M | |
| Total expenses | 6.983 M | 6.024 M | 5.213 M | 6.382 M | 6.480 M | 6.226 M | 7.610 M | |
| -13.73% | -13.46% | 22.42% | 1.54% | -3.92% | 22.23% | |||
| Operating income | -6.983 M | -6.024 M | -5.213 M | -6.382 M | -6.480 M | -6.226 M | -7.610 M | |
| Ebit | -6.983 M | -6.024 M | -5.213 M | -6.382 M | -6.480 M | -6.204 M | -7.549 M | |
| Pretax income | -6.983 M | -6.024 M | -5.213 M | -6.382 M | -6.480 M | -6.204 M | -7.549 M | |
| -13.73% | -13.46% | 22.42% | 1.54% | -4.26% | 21.68% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -6.834 M | -5.883 M | -5.101 M | -6.312 M | -6.408 M | -6.204 M | -7.549 M | |
| 13.92% | 13.29% | -23.74% | -1.52% | 3.18% | -21.68% |